Building a Cancer Medtech Company the Hard Way: Shaun Bagai on Evidence, Strategy, and Growth

Drug launches in oncology don’t succeed simply because the technology works; they succeed when the evidence is strong enough to change physician behavior. In this episode of Pharma Sessions, host Jonathan Kaskey is joined by Shaun Bagai, CEO of RenovoRx, to discuss the long and uncertain journey of building a medtech company grounded in clinical proof. From turning down medical school to leading a Nasdaq-listed oncology company, Shaun shares how physician feedback reshaped the company’s strategy, why investing in rigorous clinical trials can be a defining leadership decision, and why face-to-face relationships remain essential for market adoption in healthcare. Pharma Sessions provides general insights into the pharmaceutical and life sciences industry through conversations with its guests. The content shared in this podcast is for informational purposes only and should not be considered medical, legal, regulatory, or financial advice. The use of any information discussed in this episode or materials linked from the podcast is at the listener’s own risk. The views and opinions expressed by guests are their own and do not necessarily reflect the views of Jonathan Kaskey, Pharma Sessions, its sponsors, or affiliated organizations.

After stepping away from the traditional path to medical school, Shaun Bagai pursued a different way to impact patient care: building technologies that change how treatments reach patients. That path eventually led him to RenovoRx, where the challenge wasn’t just developing innovative oncology technology; it was proving its value in a clinical environment that demands rigorous evidence.

In this episode of Pharma Sessions, host Jonathan Kaskey sits down with Shaun Bagai, CEO of RenovoRx, to unpack the 11-year journey of scaling a two-person startup into a Nasdaq-listed company advancing Phase 3 trials. Bagai shares why physician feedback forced a complete commercial pivot, how prioritizing clinical evidence over quick exits shaped the company’s trajectory, and why real-world relationships with clinicians remain one of the most powerful advantages in healthcare commercialization.

What You’ll Learn:

Why saying "no" to your board's quick-flip strategy was the inflection point
How to identify when physician feedback should reshape your commercial roadmap
The irreplaceable competitive advantage of face-to-face field presence
How to build a lean, efficient salesforce without sacrificing market intelligence
The leadership paradox of staying hands-on in a small organization
Why turning down med school and stable Medtronic roles paid off, and how to evaluate your own "leap" decision

Shaun Bagai is CEO of Renovo RX, a NASDAQ-listed oncology company pioneering transarterial micro perfusion, a breakthrough drug delivery platform that localizes chemotherapy directly to tumors. With over two decades of experience spanning clinical research, regulatory affairs, and commercial strategy across Medtronic, Heartflow, and multiple high-impact startups, Bagot has built a reputation for translating early-stage innovation into scalable, evidence-based solutions.

Disclaimer: Pharma Sessions is for informational purposes only and does not constitute medical, legal, or financial advice. Guest opinions are their own and do not reflect the views of the host or sponsors. Use of any information provided is at the listener’s own risk and does not imply endorsement of specific products or strategies.

Episode Resources:

RenovoRx Website: https://renovorx.com/
Shaun Bagai on LinkedIn: https://www.linkedin.com/in/shaun-r-bagai/
Jonathan Kaskey on LinkedIn: https://www.linkedin.com/in/jonkaskey/
XSUNT Corporation Website: http://www.xsunt.com/

Or join the Pharma Sessions Substack:
www.pharmasessions.substack.com